New England Journal of Medicine publishes results from pivotal phase III BELIEVE trial of Reblozyl in adult patients With beta thalassemia- BMS
Related news and insights
bluebird bio, Inc. presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobin for beta-thalassemia) in patients with transfusion-dependent beta-thalassemia (TDT).
Bristol Myers Squibb and Acceleron Pharma Inc. announced that the European Commission (EC) has approved Reblozyl (luspatercept) for the treatment of: 1. Adult patients with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based therapy.